EA027046B1 - Биоразлагаемая композиция для доставки лекарственных средств, способ ее получения и ее применение - Google Patents

Биоразлагаемая композиция для доставки лекарственных средств, способ ее получения и ее применение Download PDF

Info

Publication number
EA027046B1
EA027046B1 EA201390783A EA201390783A EA027046B1 EA 027046 B1 EA027046 B1 EA 027046B1 EA 201390783 A EA201390783 A EA 201390783A EA 201390783 A EA201390783 A EA 201390783A EA 027046 B1 EA027046 B1 EA 027046B1
Authority
EA
Eurasian Patent Office
Prior art keywords
biodegradable
block copolymer
composition
repeating units
polyethylene glycol
Prior art date
Application number
EA201390783A
Other languages
English (en)
Russian (ru)
Other versions
EA201390783A1 (ru
Inventor
Жорж Годриол
Original Assignee
Мединселл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45809329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA027046(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Мединселл filed Critical Мединселл
Publication of EA201390783A1 publication Critical patent/EA201390783A1/ru
Publication of EA027046B1 publication Critical patent/EA027046B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/08—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing solids as carriers or diluents
    • A01N25/10—Macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/66—Polyesters containing oxygen in the form of ether groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
    • C08L67/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Polymers & Plastics (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Agronomy & Crop Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Environmental Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
EA201390783A 2010-12-29 2011-12-29 Биоразлагаемая композиция для доставки лекарственных средств, способ ее получения и ее применение EA027046B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061428007P 2010-12-29 2010-12-29
PCT/IB2011/003323 WO2012090070A2 (en) 2010-12-29 2011-12-29 Biodegradable drug delivery compositions

Publications (2)

Publication Number Publication Date
EA201390783A1 EA201390783A1 (ru) 2013-12-30
EA027046B1 true EA027046B1 (ru) 2017-06-30

Family

ID=45809329

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390783A EA027046B1 (ru) 2010-12-29 2011-12-29 Биоразлагаемая композиция для доставки лекарственных средств, способ ее получения и ее применение

Country Status (35)

Country Link
US (9) US9023897B2 (zh)
EP (3) EP2658525B1 (zh)
JP (2) JP6134269B2 (zh)
KR (1) KR101741055B1 (zh)
CN (1) CN103491946B (zh)
AU (1) AU2011350898B2 (zh)
BR (1) BR112013016662B1 (zh)
CA (1) CA2822854C (zh)
CL (1) CL2013001942A1 (zh)
CO (1) CO6751290A2 (zh)
CU (1) CU24203B1 (zh)
CY (1) CY1119829T1 (zh)
DK (1) DK2658525T3 (zh)
EA (1) EA027046B1 (zh)
ES (3) ES2733915T3 (zh)
FI (1) FI3586825T3 (zh)
HR (1) HRP20171810T1 (zh)
HU (1) HUE037349T2 (zh)
IL (1) IL227235A (zh)
LT (1) LT2658525T (zh)
MA (1) MA34832B1 (zh)
ME (1) ME02915B (zh)
MX (1) MX347090B (zh)
MY (1) MY165655A (zh)
NO (1) NO2658525T3 (zh)
NZ (1) NZ612326A (zh)
PL (3) PL2658525T3 (zh)
PT (1) PT2658525T (zh)
RS (1) RS56550B1 (zh)
SG (2) SG191414A1 (zh)
SI (1) SI2658525T1 (zh)
TN (1) TN2013000267A1 (zh)
UA (1) UA112069C2 (zh)
WO (1) WO2012090070A2 (zh)
ZA (1) ZA201304687B (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX353280B (es) * 2012-06-27 2018-01-05 Medincell Suministro de farmaco biodegradable para las composiciones hidrofobicas.
ES2875957T3 (es) 2012-12-20 2021-11-11 Amgen Inc Agonistas del receptor APJ y usos de los mismos
EP2896402A1 (en) 2014-01-20 2015-07-22 Vect-Horus Activated neurotensin molecules and the uses thereof
WO2015110915A2 (en) 2014-01-27 2015-07-30 Medincell Retro-inverso analogs of spadin display increased antidepressant effects
FR3027522B1 (fr) 2014-10-27 2016-12-09 I Ceram Composition poreuse chargee en principe actif
AU2016229595B2 (en) * 2015-03-12 2019-08-29 Kuros Biosciences B.V. Anhydrous biocompatible composite materials
HUE063850T2 (hu) 2015-09-21 2024-02-28 Teva Pharmaceuticals Int Gmbh Hosszan tartó felszabadulású olanzapin készítmények
CA3004849C (en) * 2015-11-16 2024-06-11 Georges Gaudriault A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
WO2018091895A1 (en) 2016-11-16 2018-05-24 Persica Pharmaceuticals Ltd. Antibiotic formulations for lower back pain
CA3057438A1 (en) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
WO2019016234A1 (en) * 2017-07-17 2019-01-24 Medincell PHARMACEUTICAL COMPOSITION
KR20200060729A (ko) 2017-10-04 2020-06-01 패션 케미칼즈 게엠베하 운트 코. 카게 신규한 폴리락트산의 에스테르 및 이의 조성물
GB201900258D0 (en) * 2019-01-08 2019-02-27 Medincell Pharmaceutical composition
KR20220062372A (ko) * 2019-09-13 2022-05-16 메딘셀 에스.에이. 약물 전달 제형
CN110638963A (zh) * 2019-11-01 2020-01-03 慧生医学科技(徐州)有限公司 一种可降解缓释药物组合物及制备方法
GB202010340D0 (en) 2020-07-06 2020-08-19 Medincell Pharmaceutical composition
US20240099964A1 (en) 2020-12-16 2024-03-28 Medincell S.A. Methods and Compositions for the Prophylactic Treatment of SARS-CoV-2 virus (COVID-19)
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
KR20230158088A (ko) 2021-03-17 2023-11-17 메딘셀 에스.에이. 리스페리돈 및 생분해성 중합체를 포함하는 지속성의 주사용 제제
EP4329727A1 (en) * 2021-04-30 2024-03-06 MedinCell S.A. New formulation
KR20240117521A (ko) 2021-07-06 2024-08-01 마크 하슬레톤 세로토닌 재흡수 억제제 금단 증후군의 치료
AU2022323754A1 (en) 2021-08-05 2024-02-08 Medincell S.A. Pharmaceutical composition
WO2024052920A1 (en) * 2022-09-08 2024-03-14 Ramot At Tel-Aviv University Ltd. Programmable stimuli-responsive polymeric formulations
US20240238308A1 (en) 2023-01-10 2024-07-18 Medincell Sa Olanzapine compositions and methods of use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221534A (en) * 1989-04-26 1993-06-22 Pennzoil Products Company Health and beauty aid compositions
US6350812B1 (en) * 1995-11-29 2002-02-26 Centre National De La Recherche Scientifique (Cnrs) Hydrogels containing triblock copolymers, and preparation and use thereof
US6592899B2 (en) * 2001-10-03 2003-07-15 Macromed Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
US20050112170A1 (en) * 2003-11-20 2005-05-26 Hossainy Syed F. Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE37983T1 (de) 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
US5071643A (en) 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
EP0343850B1 (en) * 1988-05-23 1994-07-20 The Procter & Gamble Company Absorbent structures from mixed furnishes
US5632727A (en) 1988-10-03 1997-05-27 Atrix Laboratories, Inc. Biodegradable film dressing and method for its formation
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5077049A (en) 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
USRE37950E1 (en) 1990-04-24 2002-12-31 Atrix Laboratories Biogradable in-situ forming implants and methods of producing the same
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
ES2236700T3 (es) * 1993-11-19 2005-07-16 Janssen Pharmaceutica N.V. 1,2-benzazoles microencapsulados.
KR0148704B1 (ko) 1994-01-10 1998-08-17 김상응 생체분해성 약물전달용 고분자
PT754032E (pt) 1994-04-08 2002-05-31 Atrix Lab Inc Composicoes liquidas para difusao
AU4652596A (en) 1995-01-09 1996-07-31 Atrix Laboratories, Inc. Liquid polymer delivery system
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
IL118235A0 (en) 1996-05-13 1996-09-12 Univ Ben Gurion Composition and method for forming biodegradable implants in situ and uses of these implants
US5711958A (en) * 1996-07-11 1998-01-27 Life Medical Sciences, Inc. Methods for reducing or eliminating post-surgical adhesion formation
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6261583B1 (en) 1998-07-28 2001-07-17 Atrix Laboratories, Inc. Moldable solid delivery system
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
KR100416242B1 (ko) 1999-12-22 2004-01-31 주식회사 삼양사 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법
KR100446101B1 (ko) 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물
CN1290893C (zh) * 2002-05-03 2006-12-20 詹森药业有限公司 聚合物微乳状液
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
US7160551B2 (en) 2002-07-09 2007-01-09 The Board Of Trustees Of The University Of Illinois Injectable system for controlled drug delivery
US7262253B2 (en) * 2003-12-02 2007-08-28 Labopharm, Inc. Process for the preparation of amphiphilic poly (N-vinyl-2-pyrrolidone) block copolymers
US20060034889A1 (en) * 2004-08-16 2006-02-16 Macromed, Inc. Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof
CA2609268A1 (en) * 2005-05-23 2006-11-30 University Of Utah Research Foundation Echogenic microbubbles and microemulsions for ultrasound-enhanced nanoparticle-mediated delivery of agents
CN103071209A (zh) * 2005-11-17 2013-05-01 周吉尼克斯股份有限公司 用无针注射递送粘稠制剂
AR064286A1 (es) * 2006-12-13 2009-03-25 Quiceno Gomez Alexandra Lorena Produccion de dispositivos oftalmicos basados en la polimerizacion por crecimiento escalonado fotoinducida
US20090004243A1 (en) 2007-06-29 2009-01-01 Pacetti Stephen D Biodegradable triblock copolymers for implantable devices
CL2008003305A1 (es) 2007-11-06 2009-06-05 M/S Panacea Biotec Ltd Composicion inyectable que comprende un agente activo seleccionado de un grupo definido; al menos un polimero bioerosionable, al menos un solvente no toxico y opcionalmente uno o mas excipientes; proceso de preparacion; uso para tratar enfermedades mentales o cancer.
JP2010215562A (ja) 2009-03-17 2010-09-30 Kansai Univ 膨隆剤組成物および膨隆剤製造方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221534A (en) * 1989-04-26 1993-06-22 Pennzoil Products Company Health and beauty aid compositions
US6350812B1 (en) * 1995-11-29 2002-02-26 Centre National De La Recherche Scientifique (Cnrs) Hydrogels containing triblock copolymers, and preparation and use thereof
US6592899B2 (en) * 2001-10-03 2003-07-15 Macromed Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
US20050112170A1 (en) * 2003-11-20 2005-05-26 Hossainy Syed F. Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SUMING LI: "Bioresorbable Hydrogels Prepared Through Stereocomplexation between Poly(L-lactide) and Poly(D-lactide) Blocks Attached to Poly(ethylene glycol)", MACROMOLECULAR BIOSCIENCE, WILEY-VCH VERLAG GMBH, vol. 3, no. 11, 1 November 2003 (2003-11-01), pages 657 - 661, XP055034429, ISSN: 16165187, DOI: 10.1002/mabi.200350032 *

Also Published As

Publication number Publication date
EP2658525A2 (en) 2013-11-06
WO2012090070A3 (en) 2012-11-01
WO2012090070A8 (en) 2013-08-08
US20120172454A1 (en) 2012-07-05
JP6302983B2 (ja) 2018-03-28
US20160030581A1 (en) 2016-02-04
CA2822854A1 (en) 2012-07-05
US9023897B2 (en) 2015-05-05
FI3586825T3 (fi) 2023-03-20
BR112013016662A2 (pt) 2016-10-04
US20150157727A1 (en) 2015-06-11
UA112069C2 (uk) 2016-07-25
CO6751290A2 (es) 2013-09-16
EP2658525B1 (en) 2017-08-30
WO2012090070A2 (en) 2012-07-05
ES2939744T3 (es) 2023-04-26
CL2013001942A1 (es) 2014-07-04
JP2017039758A (ja) 2017-02-23
MX347090B (es) 2017-04-11
PL3257498T3 (pl) 2020-02-28
EA201390783A1 (ru) 2013-12-30
EP3586825B1 (en) 2023-01-18
US20220202942A1 (en) 2022-06-30
CU20130091A7 (es) 2013-08-29
MX2013007682A (es) 2013-10-30
ME02915B (me) 2018-04-20
HRP20171810T1 (hr) 2017-12-29
CN103491946B (zh) 2016-08-10
NO2658525T3 (zh) 2018-01-27
SI2658525T1 (en) 2018-04-30
AU2011350898A1 (en) 2013-07-11
PT2658525T (pt) 2017-11-30
MY165655A (en) 2018-04-18
US20190099495A1 (en) 2019-04-04
AU2011350898B2 (en) 2016-09-08
HUE037349T2 (hu) 2018-08-28
EP3257498A1 (en) 2017-12-20
CA2822854C (en) 2020-01-07
CU24203B1 (es) 2016-09-30
CN103491946A (zh) 2014-01-01
ES2733915T3 (es) 2019-12-03
TN2013000267A1 (en) 2014-11-10
RS56550B1 (sr) 2018-02-28
SG191414A1 (en) 2013-08-30
US20210154301A1 (en) 2021-05-27
CY1119829T1 (el) 2018-06-27
KR101741055B1 (ko) 2017-05-29
US20190192665A1 (en) 2019-06-27
EP3586825A1 (en) 2020-01-01
JP2014502613A (ja) 2014-02-03
PL3586825T3 (pl) 2023-04-11
ES2647614T3 (es) 2017-12-22
ZA201304687B (en) 2014-03-26
JP6134269B2 (ja) 2017-05-24
IL227235A (en) 2016-05-31
US20230091533A1 (en) 2023-03-23
KR20130135294A (ko) 2013-12-10
NZ612326A (en) 2014-10-31
LT2658525T (lt) 2017-12-11
BR112013016662B1 (pt) 2021-08-03
MA34832B1 (fr) 2014-01-02
DK2658525T3 (da) 2017-11-13
PL2658525T3 (pl) 2018-02-28
US20210038724A1 (en) 2021-02-11
EP3257498B1 (en) 2019-04-24
SG10201508568VA (en) 2015-11-27

Similar Documents

Publication Publication Date Title
EA027046B1 (ru) Биоразлагаемая композиция для доставки лекарственных средств, способ ее получения и ее применение
JP2013533230A5 (zh)
RU2012157244A (ru) Жидкотекучие композиции для инъекций, включающие бупренорфин
JP6057972B2 (ja) 半固体送達賦形剤および薬学的組成物
CY1109425T1 (el) Φαρμακευτικες συνθεσεις για τη χορηγηση με ελεγχομενη αποδεσμευση βιολογικα δραστικων ενωσεων
US6822000B2 (en) Bioerodible poly (orthoesters) from dioxolane-based diketene acetals
KR102505642B1 (ko) 폴리오르토에스테르 및 비프로톤성 용매의 조성물
NZ597621A (en) Sustained delivery formulations of risperidone compounds
RU2005117164A (ru) Композиции пролонгированного действия с контролируемым высвобождением
RU2008137032A (ru) Распадающиеся пероральные пленки
BR112014031773B1 (pt) composição de liberação de drogas biodegradáveis hidrofóbicas
RU2006101985A (ru) Дозированные формы анестезирующих средств с с длительным высвобождением для обезболивания
JP2005524730A5 (zh)
US20070264339A1 (en) Base-stabilized polyorthoester formulations
CA2468703A1 (en) Controlled release polymeric compositions of bone growth promoting compounds
RU2010149561A (ru) Твердое лекарственное средство с замедленным высвобождением действующих веществ
RU2011136636A (ru) Фармацевтическая композиция для орального введения
US20020176844A1 (en) Bioerodible polyorthoesters containing hydrogen bonding groups
CN101787135B (zh) 一种基于聚乙二醇的网状结构高分子凝胶及其制备方法
HRP20231667T1 (hr) Farmaceutski pripravak
US20030187054A1 (en) Preparations for chondrogenesis
Babanejad Developing Cryogel Composites to Combat Prescription Opioid Abuse
JPH0539347A (ja) 生分解性重合体
JPWO2021064550A5 (zh)

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG MD TJ TM